


---

# JAHRESBERICHT UVCM HEPATOLOGIE 2016



**u<sup>D</sup>**

UNIVERSITÄT  
DUISBURG  
ESSEN

**INSELSPITAL**

Universitätsklinik für  
Viszerale Chirurgie und Medizin

## **Jahresbericht Hepatologie 2016**

Universitätsklinik für Viszerale Chirurgie und Medizin UVCM  
Hepatology  
Inselspital  
3010 Bern  
Tel +41 31 632 87 11  
Fax +41 31 632 49 97

**Prof. Jean-François Dufour**  
[jean-francois.dufour@dkf.unibe.ch](mailto:jean-francois.dufour@dkf.unibe.ch)  
**Monique Obertin**  
[monique.obertin@dkf.unibe.ch](mailto:monique.obertin@dkf.unibe.ch)  
[www.swissliver.ch](http://www.swissliver.ch)

## Inhaltsverzeichnis

	<i>Seite</i>
1. Rückblende	4
2. Veranstaltungen	6
3. Vorträge an nationalen und internationalen Veranstaltungen	10
4. Klinische Studien	20
5. Stiftung für Leberkrankheiten	23
6. Fondation Suisse contre le cancer du foie	24
7. Personelles und Liste der Mitarbeitenden	25
8. Verzeichnis der Drittmittel 2016	28
9. Lehrleistungen	29
10. Publikationen	30



## 1. Rückblende

Die Berner Hepatologie blickt auf ein äusserst aktives und erfolgreiches Berichtsjahr zurück. Die Poliklinik des Bauchzentrums konnte im Jahr 2016 wiederum einen Anstieg der Patientenzahlen verzeichnen. Bei den einzelnen Untersuchungen ergaben sich Zunahmen von 40 % bei den Konsilien in der Poliklinik, 16% bei den Sonographien, und 13% bei den transjugulären Biopsien.

Die 6 Hepatologie-Symposien 2016 widmeten sich wiederum aktuellen Themen aus der Hepatologischen Praxis und stiessen bei den zahlreichen Teilnehmenden auf grosses Interesse. Am 3. November fand in Zürich ein weiterer HCC Day statt.

Prof. Dr. Andrea De Gottardi und Prof. Dr. Annalisa Berzigotti, beide leitende Aerzte der Hepatologie, wurden per 1. April 2016 zum assoziierten Professor, bzw. zur assoziierten Professorin, ernannt.

Prof. Berzigotti wurde ausserdem zum Mitglied des Wissenschaftlichen Komitees im Governing Board der European Association for the Study of the Liver (EASL), zur Visiting Professorin der Universität Belgrad, zum Mitglied der Editorial Boards von Digestive and Liver Disease sowie von Seminars in Liver Disease gewählt.

Das Team der Kaderärzte konnte um Dr. Stefania Casu aus Italien erweitert werden.

Einen Riesenerfolg erzielte die gesamte Universitätsklinik für Viszerale Chirurgie und Medizin mit ihrem Tag der offenen Tür, am 5. November 2016. Von 10 bis 16 Uhr hatten Besucherinnen und Besucher die Gelegenheit, sich in den Räumlichkeiten des UVCM Bauchzentrums umzuschauen. Unter den Gästen befanden sich zuweisende Aerztinnen und Aerzte, Patientinnen und Patienten mit ihren Familien sowie Mitarbeitende der Inselgruppe und Interessierte.

Ein reichhaltiges Angebot an informativen und unterhaltsamen Attraktionen wurden dem Publikum geboten: Nebst aktuellen Informationen zu neuen Diagnostik- und Therapiemethoden gab es die Möglichkeit, sich in der Handhabung mit medizinischen Geräten zu üben. Verpflegung, Wettbewerbe sowie eine Spielecke rundeten das Programm ab. Die Besucher/innenzahl betrug mehr als 500 Personen.

Am 22. Januar trafen sich die Forschungsgruppen der Universitätsklinik für Viszerale Chirurgie und Medizin wiederum auf dem Gurten zu Diskussion und Austausch unpublizierter Daten.

Dr. Stirnimann führte wiederum einen swissethics-anerkannten GCP-Kurs für das Level „Investigator“ durch. Interne und externe Referenten vermittelten Wissenswertes und Praxisnahes zu relevanten Themen der regulativen und technischen Abwicklung von klinischen Forschungsprojekten (Ethikkommission, Unitectra, Swissmedic, Statistik, Finanzierung, etc.).

## **2. Veranstaltungen**

**UVCM Research Retreat**, 22. Januar 2016

### **Hepatologie-Symposien**

#### **Liver Fibrosis, 25. Februar 2016**

*Dr. PhD Jordi Gracia-Sancho, Barcelona, Spanien, über: Liver Sinusoidal Endothelium: New Player in Liver Fibrosis.*

*Prof. Wim Lalemann, MD PhD, KU Leuven, Belgien, über: Farnesoid X Receptor Agonism in Chronic Liver Disease.*

#### **Coagulation and Portal Hypertension, 12. Mai 2016**

*Prof. Dominique Thabut, Paris, Frankreich, über: Prevention of Variceal Rebleeding: What Really Improves Outcome?*

*Prof. Ton Lisman, Groningen, Niederlande, über: Treating Chronic Liver Disease with Anticoagulants: Rationale and Pitfalls.*

#### **Viral Hepatitis, 23. Juni 2016**

*Prof. Tarik Asselah, Clichy, Frankreich, über: HCV Therapy of Decompensated Cirrhosis.*

*Prof. Fabien Zoulim, Lyon, Frankreich, über: Hepatitis B: Is a Cure Possible?*

#### **Portopulmonary Hypertension, 8. September 2016**

*Olivier Sitbon, Kremlin-Bicêtre, Frankreich, über: Portopulmonary Hypertension: Why to Detect and Treat?*

*Prof. Roberto Rodriguez-Roisin, Barcelona, Spanien, über: Diagnosis and Treatment of Hepato-Pulmonary Syndrome.*

#### **Cholestatic Liver Diseases, 15. September 2016**

*Prof. Ulrich Beuer, Asterdam, Niederlande, über: IgG4 Cholangiopathy.*

*Prof. Gideon Hirschfield, Birmingham, UK, über: New Treatments for PBC.*

# NASH, 24. November 2016

PD Dr. Stefano Romeo, Gothenburg, Schweden, über: Place of the Genetic in NASH Management.


Prof. Sven Francque, Edegem, Belgien, über: New Treatments for NASH.

## SYMPOSIA 2016



Universitätsspital für Viszerale Chirurgie und Medizin  
 Abteilungen:  
 Prof. Dr. med. Dr. h. c. Daniel Candinas, Viszeralchirurgie  
 Prof. Dr. med. Andreas G. Klöppel, Gastroenterologie  
 Prof. Dr. med. Jean-François Durier, Hepatologie

### 1<sup>st</sup> Symposium HEPATOLOGY 2016



Thursday, 20<sup>th</sup> February, 2016  
 18:00-20:00  
 Inselspital, Kinderklinik, Level A, Room 1


We are looking forward to welcoming you to the following programme:

18:00



Universitätsspital für Viszerale Chirurgie und Medizin  
 Abteilungen:  
 Prof. Dr. med. Dr. h. c. Daniel Candinas, Viszeralchirurgie  
 Prof. Dr. med. Andreas G. Klöppel, Gastroenterologie  
 Prof. Dr. med. Jean-François Durier, Hepatologie

### 3<sup>rd</sup> Symposium HEPATOLOGY 2016



Viral Hepatitis

Thursday, 27<sup>th</sup> June, 2016  
 18:00-20:00  
 Inselspital, Frauenklinik, Room D102

We are looking forward to welcoming you to the following programme:

18:00 Welcome by PD Dr. med. Nassor Senno, Hepatology, Inselspital, University Hospital Bern

18:05 Prof. Tarik Asselah, Division of Hepatology, Beauguon Hospital, Clercy, University Paris 7, Clermont, Paris, France

Lecture title: "HCV therapy of decompensated cirrhosis"  
 Discussion

18:50



Universitätsspital für Viszerale Chirurgie und Medizin  
 Abteilungen:  
 Prof. Dr. med. Dr. h. c. Daniel Candinas, Viszeralchirurgie  
 Prof. Dr. med. Andreas G. Klöppel, Gastroenterologie  
 Prof. Dr. med. Jean-François Durier, Hepatologie

### 5<sup>th</sup> Symposium HEPATOLOGY 2016

Thursday, 15<sup>th</sup> September, 2016  
 18:00-20:00  
 Inselspital, Baschiatorium, Room A316



Cholestatic Liver Diseases

We are looking forward to welcoming you to the following programme:

18:00 Welcome by Dr. med. Guido Stimmann, Hepatology, Inselspital, University Hospital Bern

18:05 Prof. Marco Beuers, Gastroenterology and Hepatology (Tiger Institute for Liver and Intestinal Research), University of Amsterdam, the Netherlands  
 Lecture title: "Spherohepatology"  
 Discussion



Universitätsspital für Viszerale Chirurgie und Medizin  
 Abteilungen:  
 Prof. Dr. med. Dr. h. c. Daniel Candinas, Viszeralchirurgie  
 Prof. Dr. med. Andreas G. Klöppel, Gastroenterologie  
 Prof. Dr. med. Jean-François Durier, Hepatologie

### 2<sup>nd</sup> Symposium HEPATOLOGY 2016



Thursday, 12<sup>th</sup> May, 2016  
 18:00-20:00  
 Inselspital, Frauenklinik, Room D102

We are looking forward to welcoming you to the following programme:

Welcome by Prof. Andrea Di Corleto, Hepatology, Inselspital, University Hospital Bern  
 Prof. Dominique Thabut, Division of Hepato-Gastroenterology



Universitätsspital für Viszerale Chirurgie und Medizin

### Invitation to the 4<sup>th</sup> Symposium HEPATOLOGY 2016



Thursday, 01<sup>st</sup> September, 2016  
 18:00-20:00  
 Inselspital, Frauenklinik, Room D017

PORTOPULMONARY HYPERTENSION



### 6<sup>th</sup> Symposium HEPATOLOGY 2016



Thursday, 24<sup>th</sup> November, 2016  
 18:00-20:00  
 Inselspital, Baschiatorium, Room A316

We are looking forward to welcoming you to the following programme:

### **3rd Annual HEP Preceptorship, 9.-10. Juni 2016**

Mit 7 Sessions zu den Schwerpunkten:

Diagnosis in Hepatology

Work-up in Chronic Liver Diseases

Prevention of Complications in the Cirrhotic Patient

Surgical and Interventional Therapy in Hepatology

Management of Special Situations

Understanding of Chronic Liver Disease

Medical Therapy in Hepatology

### **Swiss Meeting Liver Transplantation 2016, 5. Februar 2016**

#### **HCC Day 3. November 2016**

Prof. Edoardo G. Giannini, Genova, Italien, über: Surveillance. The Case of NAFLD.

Prof. Philipp Dutkowsky, Zürich, Schweiz, über: De Novo or Salvage Tx.

Prof. J.-F. Blanc, Bordeaux, Frankreich, über: Immunotherapy to Treat HCC.

Prof. Alban Denys, Lausanne, Schweiz, über: Get the Maximum out of SIRT.

Dr. Maria Reig, Barcelona, Spanien, über: New Treatments of HCV and HCC.



3<sup>rd</sup> annual HEP Preceptorship

### **IMPROVING OUTCOMES IN CHRONIC LIVER DISEASE**

Spittelsaal, GenerationenHaus  
and Bauchzentrum, Inselspital, Berne,  
Switzerland

**JUNE, 9-10, 2016**



**Tag der offenen Tür, 5. November 2016**  
Aktuelle Informationen zu neuen Diagnostik- und  
Therapiemethoden für ein breites Publikum.



**EINLADUNG  
TAG  
DER OFFENEN  
BAUCHZENTRUM  
ZENTRUM TÜR**

**SAMSTAG, 05. 11. 16, 10.00 – 16.00 UHR**

**Programm**

- Experimentieren Sie mit chirurgischen Geräten
- Versuchen Sie, eine Darmspiegelung am Modell durchzuführen
- Machen Sie einen Ultraschall der Leber
- Nähen Sie wie ein richtiger Chirurg
  - Entdecken Sie Ihre Zellen unter dem Mikroskop
- Blossieren Sie eine Leber
- Staunen Sie über die hochspezialisierte Computer-navigierte Bauchspeicheldrüsenchirurgie
- Messen Sie Ihren Blutzucker und Blutdruck
- Erfahren Sie mehr über Darmkrebsvorsorge, entzündliche Darmerkrankungen und Virushepatitis
  - Diskussionsmöglichkeiten mit Spezialisten
  - Und vieles mehr

**Kinderprogramm**

- Kinderschinken
- Medizinische Spielecke
- Teddyspital für Teddybären (bring Deinen kranken Teddy mit)

**Rahmenprogramm**

- Imbiss und Getränke
- Wettbewerb mit tollen Preisen – Hauptpreis: i-pad

Prof. Dr. med. Dr. h.c. Daniel Candinas, Prof. Dr. med. Andrew Macpherson, Prof. Dr. med. Jean-François Durfar  
Klinikdirektoren für Viszerale Chirurgie und Medizin  
[www.bauchzentrum-bern.ch](http://www.bauchzentrum-bern.ch)

**INSELSPITAL**  
Universitätsklinik für  
Viszerale Chirurgie und Medizin

**Bauchzentrum  
BERN**

## **DKF Research Conference, 4. April 2016**

Prof. Dr. Marc Solioz, Laboratory of Biochemistry and Molecular Biology, Tomsk State University, Tomsk, RU, über: Antimicrobial Copper Materials for Hygiene and Infection Prevention - Too Good to be True?

## **2jähriges systematisches Weiterbildungs-Curriculum für Allgemeine Innere Medizin, 23. Februar.16**

Dr. G. Stirnimann, UVCM Hepatologie Bern, über Hepatotoxizität: Alkohol und andere Noxen

### 3. Vorträge an nationalen und internationalen Veranstaltungen

#### Prof. Dr. J.-F. Dufour

Liver transplantation: a changing world'. Swiss Transplantation Society. 14th Annual Meeting. February 2016.

Tests hépatiques perturbés, que faire?' Demi-journée de formation continue. Société Neuchâteloise de médecine. Neuchâtel. Mars 2016.

Treatment of NASH'. Falk Symposium. Gut Liver Interactions: from IBD to NASH. Innsbruck. March 2016.

HCC. Liver biopsy from the clinician perspective'. International Liver Meeting. Annual Meeting EASL. Barcelona. April 2016.

HCC and metabolomic'. Meeting del Martedì. Padova. April 2016.

Predicting outcomes in NASH'. EASL single topic conference 'NASH beyond the acronym'. Riga. May 2016.

HCC in NAFLD'. Meeting of the Czech Hepatology Society. Karlovy Vary. May 2016.

Hépatite C: quand il ne faut pas perdre le foie'. Fachsymposium 2016. Biel. June 2016.

Lifestyles and HCC'. Paris NASH Symposium. Paris. June 2016.

Hepatocellular carcinoma'. Annual Meeting Swiss Society of Gastroenterology. Interlaken. September 2016.


Bern HCC Cohort'. Seminario: Terapia del carcinoma epatocellulare in stadio intermedio-avanzato. Lugano. September 2016.

UEG 2016: Liver Summary'. Swiss Perspectives. UEG. Vienna. October 2016.

Non-invasive diagnosis of NASH'. UEG. Vienna. October 2016.

Liver nodule in cirrhotic patient'. UEG. Vienna. October 2016.

Carcinome hépatocellulaire. Mis à jour 2016-17.' Course de formation postgraduée et continue en médecine interne. Neuchâtel. Novembre 2016.





## Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma

Professor Jean-François Dufour, MD

Head of Hepatology  
 Director University Clinic for Visceral Surgery and Medicine  
 University of Berne  
 Berne, Switzerland



**INSELSPITAL**   
 UNIVERSITÄTSPITAL BERNE  
 HOSPITAL UNIVERSITÄT DE BERNE  
 BERNE UNIVERSITY HOSPITAL




## PREDICTING OUTCOMES IN NASH

Professor Jean-François Dufour, MD

Director of the University Clinic  
 for Visceral Surgery and Medicine  
 University of Berne  
 Berne, Switzerland

Friday 13th May 2016  
 12:30-13:00



Symposium 201  
 Innsbruck, Austria 11-12, 2016  
 Gut-Liver Interactions  
 From H2O to H2A20  
 Innsbruck, Austria

## TREATMENT OF NAFLD



Professor Jean-François Dufour

Director  
 University Clinic of Visceral Surgery and Medicine, Hepatology  
 University Hospital of Berne  
 Berne, Switzerland



## Session 4 A Changing World

Indications - Treatment - Outcome

## Liver Transplantation

Professor Jean-François Dufour

Director  
 University Clinic for Visceral Surgery and Medicine, Hepatology  
 University of Berne  
 Berne, Switzerland



**Prof. Dr. med. Dr. phil. nat. Andrea De Gottardi**

Alfapump: real world data from the post-marketing surveillance registry. ILC 2016, EASL Barcelona.

Ascites, SBP and hepatorenal syndrome, 17. Fortbildungskurs SGG/SSG, Brunnen, 2016.

Was muss der Rheumatologe wissen zu den viralen Hepatitiden? 12. Berner FB-Kurs für klinische Immunologie und Rheumatologie, Bern, 2016.

IgG4 related liver and biliary disease, First Swiss Autoimmune Disease Meeting, Lugano, 2016.

Management of portal vein thrombosis, SGGSSG Annual Congress, Interlaken, 2016.

**Prof. Dr. med. Dr. phil. nat. Annalisa Berzigotti**

Transjugular Intrahepatic Porto-Systemic Shunt (TIPS). Journal Club. Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Bern, June 15, 2016

Erfassung von Leberzirrhose und portaler Hypertonie: invasive und nicht-invasive Methoden. Antrittsvorlesung – Medizinische Fakultät. Universität Bern, Inselspital, August 2016.

HVPG Messung und transjuguläre Leberbiopsie Sicherheit: Erfahrung im Inselspital. Lunch for Liver interventions and innovations. Inselspital, Bern, Oktober 2016.

ICH E6 Good Clinical Practice: Core Principles. Good Clinical Practice Course. Inselspital, Bern, November 2016.

Adipositas und Leberzirrhose. Weiterbildung an der Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Bern, Dezember 2016.

Focal liver lesions: role of ultrasound. Berner Sono-Chränzli, Inselspital, Bern, Dezember 2016.

Trial Master File, Investigator Site File, Essential Documents, Quality Control & Quality Assurance. Good Clinical Practice Course. Inselspital, Bern, Dezember 2016.

Epidemiology and natural history of the Metabolic Syndrome and the liver. XXVII Symposium- Associazione ONLUS Roberto Farini, University of Padova, Italien, Januar 2016.

Cirrhosis and Portal Hypertension. Diagnostic ultrasound and elastography in Hepatology course. Spanish Association for the Study of the Liver (AEEH). Madrid, Spanien, Februar 2016.

Elastography and CEUS for the assessment of portal hypertension. Disorders of hepato-portal Circulation. University Hospital Dubrava, Zagreb, Kroatien, März 2016.

Evaluation and Risk Stratification. Baveno VI statements and goals for Baveno VII. EASL-BAVENO Joint Workshop. The International Liver Congress (EASL), Barcelona, Spanien, April 2016.

Assessing portal hypertension in patients with cirrhosis: can we skip HVPG measurement and diagnostic endoscopy? Congress (EASL), Barcelona, Spanien, April 2016.

Symposium Disease staging and prognosis: update on invasive and non-invasive methods. The International Liver Congress (EASL), Barcelona, Spanien, April 2016.

Ultrasound elastography in non-alcoholic fatty liver disease. EASL & EFSUMB Ultrasound Elastography workshop. The International Liver Congress (EASL), Barcelona, Spanien, April 2016.

International mobility and International networking. Young Investigator forum - How to become an independent researcher. The International Liver Congress (EASL), Barcelona, Spanien, April 2016.

Imaging in clinical decision making of portal vein thrombosis: a clinicians' point of view. Seminars of the School of Gastroenterology. University of Milano, Italien, Mai 2016.

Assessing portal hypertension in patients with cirrhosis: can we skip HVPG measurement and diagnostic endoscopy?. Liver Club, University of Milano, Italien, Mai 2016.

Do we need liver biopsy? No, never. Preceptorship Improving outcomes in chronic liver disease. Bern, Juni 2016.

Expert roundtable "bridging the 'Know-do gap' in Hepatitis C: How to solve the fragmentation between policy, scientific capacity and ground level solutions? The Economist Group, Genf, September 2016.

Non-invasive Staging of chronic hepatitis: international Guidelines. AISF-SIUMB-SIMIT Joint Course on "Liver Fibrosis", Gallipoli, Italien, Oktober 2016.

Contrast-enhanced ultrasound and portal hypertension. Contrast-enhanced ultrasound EFSUMB endorsed Course. Hospital Clinic, Barcelona, Spanien, Oktober 2016.

Assessment of portal hypertension in patients with cirrhosis: state of the art and future challenges. Visiting Professor Conference. University of Belgrad, Serbien, Oktober 2016.

Obesity and advanced liver disease. 4th Transylvanian Meeting for Liver Interventions. Cluj Napoca, Rumänien November 2016.

Use of invasive and non-invasive diagnostic methods for risk stratification in cirrhosis. Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo. September 2015.

Non-invasive Diagnosis of Portal Hypertension. United European

Gastroenterology Week (UEGW), Barcelona. Oktober 2015.

**Prof. Dr. med. Dr. phil. nat. Jaime Bosch**

Regulation of Hepatic Vascular Tone in Chronic Liver Disease. 15th Hepatobiliary and Gastrointestinal Research Retreat. Engelberg, Januar 2016. Portal hypertension, news and views year 2016. 12<sup>o</sup> Workshop "Hot topics in Hepatology". Módena, Italien, Januar 2016.

Highlights on portal hypertension at the 2015 AASLD Meeting. Hepatitis Master Class. Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico. Milano, Italien, Januar 2016.

A Berzigotti(1) | A Albillos(2) | C Villanueva(3) | J Genescá(4) | A Ardevol(3) | S Agustín(4) | JL Calleja(5) | R Bañares(6) | JC García-Pagán(1) | F Mesonero(2) | J Bosch (1) | Grupo Colaborativo SportDiet(7)  
1-Hemodinámica Hepática, Hospital Clinic, Barcelona y CIBERehd | 2-Hospital Universitario Ramón y Cajal, Madrid, CIBERehd | 3-Hospital Santa Creu i Sant Pau, Barcelona, CIBERehd | 4-Hospital Universitari Vall d'Hebron, Barcelona, CIBERehd | 5-Hospital Puerta de Hierro, Madrid, CIBERehd | 6-Hospital General Universitario Gregorio Marañón, Madrid, CIBERehd | 7-CIBEREHD. Efectos de la pérdida de peso por un programa de dieta y ejercicio sobre la presión portal en pacientes cirróticos obesos: estudio sportdiet. Sesión General 3. XLI Congreso Anual de AEEH, febrero 2016, Madrid (Oral Presentation).

A. Baiges, B. Procopet, G. Silva-Junior, E. Llop, A. Darnell, F. Turon, A. García-Criado, J. L. Calleja, V. Hernández-Gea, J. Bosch, JC. García-Pagán, Grupo REHEVASC. Incidencia de retrombosis en pacientes con trombosis portal no cirrótica no tumoral. Estudio prospectivo observacional. 1-Laboratorio de Hemodinamica Hepatica. Servicio de Hepatología. Hospital Clinic de Barcelona-IDIBAPS. Universitat de Barcelona. | 2-Servicio Aparato Digestivo, Hospital Puerta de Hierro, Majadahonda, Madrid | 3-Servicio de Radiología, CDI. Hospital Clínic de Barcelona. | 4-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) | 5-Registro Enfermedades HEpáticas VASculares. XLI Congreso de la AEEH, Madrid 17-19 febrero de 2016 (Congress presentation).

M. Vilaseca Barceló, C. Isabel López Sanjurjo, E. Lafoz, H. García-Calderó, O. García-Irigoyen, M. Ávila, JC. Reverter, J. Bosch, V. Hernández-Gea, J. Gracia-Sancho, JC García-Pagán. El anticoagulante oral directo rivaroxaban reduce la presión portal en ratas cirróticas mediante la desactivación de las células hepáticas estrelladas y reducción de la microtrombosis hepática. 1-Barcelona Hepatic Hemodynamic Lab - IDIBAPS - Hospital Clínic de Barcelona - CIBEREHD | 2-Universidad de Barcelona - Facultad de Medicina Campus Clínic | 3-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) | 4-Centro de Investigación Médica Aplicada (CIMA), División de Hepatología y

Terapia Génica, Universidad de Navarra, Pamplona. | 5-Departamento de Hemoterapia y Hemostasis, Hospital Clínic, Barcelona. XLI Congreso de la AEEH, Madrid 17-19 febrero de 2016 (Congress presentation).

R Maeso-Díaz, A Fernández-Iglesias, M Ortega-Ribera, J Bosch, J Gracia-Sancho. El sinusoides hepático ¿está preparado para envejecer? 1-Barcelona Hepatic Hemodynamic Lab - IDIBAPS - Hospital Clínic de Barcelona - CIBEREHD | 2-Universidad de Barcelona - Facultad de Medicina Campus Clínic. XLI Congreso de la AEEH, Madrid 17-19 febrero de 2016 (Poster presentation).

DM Tripathi | E Lafoz | H Garcia-Caldero | JC GarciaPagan | J Gracia-Sancho | J Bosch. 1-Barcelona Hepatic Hemodynamic Lab - IDIBAPS - Hospital Clínic de Barcelona - CIBEREHD | 2-Universidad de Barcelona - Facultad de Medicina Campus Clínic. Simvastatina previene el empeoramiento de la disfunción microvascular hepática causada por la endotoxemia en ratas con cirrosis. XLI Congreso de la AEEH, Madrid 17-19 febrero de 2016 (Poster Presentation).

F Turon | A Baiges | Á Garcia-Criado | R Gilabert | C Bru | A Berzigotti | JC Reverter | S Seijo | J Bosch | V Hernández-Gea | JC Garcia-Pagán. 1-Laboratorio de Hemodinamica Hepatica. Servicio de Hepatología. Hospital Clínic de Barcelona-IDIBAPS. Universitat de Barcelona. | 2-Servicio de Radiología, CDI. Hospital Clínic de Barcelona. | 3-Servicio de Hemoterapia y hemostasia. Hospital Clínic de Barcelona. | 4-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Factores pronosticos de desarrollo de trombosis del eje esplenoportal en pacientes con cirrosis hepática. XLI Congreso de la AEEH, Madrid 17-19 febrero de 2016 (Poster Presentation).

F Turon | C Noronha Ferreira | S Seijo | A Baiges | A Plessier(2) | G Silva-Junior | J Bosch | V Hernández-Gea | D Valla (2) | JC Garcia-Pagán. 1-Laboratorio de Hemodinamica Hepatica. Servicio de Hepatología. Hospital Clínic de Barcelona-IDIBAPS. Universitat de Barcelona. | 2-Service d'Hépatologie. Hôpital Beaujon. Clichy. France. | 3-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Historia natural de las varices gastro-esofágicas en pacientes con trombosis venosa portal no cirrótica y no tumoral. XLI Congreso de la AEEH, Madrid 17-19 febrero de 2016 (Poster Presentation).

Bosch J. The Baveno cooperation: What it is, how it works, what are the goals. Joint Workshop EASL-Baveno. EASL International Liver Congress Barcelona, Spain, April 2016.

General Session 4. General Hepatology (Cirrhosis, transplantation and tumour) EASL LiverTree™. Bosch J. Apr 17, 2016; EASL International Liver Congress April 13-17, 2016. Barcelona, Spain (Chair).

M Vilaseca (1), C Lopez-Sanjurjo(1), E Lafoz(1), H Garcia-Calderó(1),

O Garcia-Irigoyen(2), M Avila(2), JC Reverter (3), J Bosch (1),V Hernandez-Gea(1), J Gracia-Sancho(1), JC Garcia-Pagán(1).1-Hepatic Hemodynamic Lab Liver Unit.ICMDIM,IDIBAPS,CIBERehd,Barcelona;2-Centro de Investigación Médica Aplicada (CIMA) Hepatology and Gene Therapy,CIBERehd,University of Navarra,Pamplona;3-Hemotherapy and Hemostasis Dpt, Hospital Clínic, Barcelona,Spain. Abstract SAT-415: Rivaroxaban reduces portal hypertension in cirrhotic rats by deactivating hepatic stellate cells and reducing intrahepatic microthrombosis. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster presentation).

PR Shea\* , A Sanyal, DC Rockey, R Loomba, AM Diehl, SE Kleinstein, RP Myers, GM Subramanian, JG McHutchison, MF Abdelmalek, V Ratziu, N Afdhal, S Harrison, J Bosch, DB Goldstein, \*United States. Genome-wide association study of clinically significant portal hypertension in patients with nonalcoholic steatohepatitis and advanced fibrosis. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster Presentation).

Afdhal N, Asselah T, Everson GT, Bosch J, De-Oertel S, Brainard DM, McHutchinson JG, Yang Y, Watt KD, Curry M, Gane E.1-Beth Israel Deaconess Medical Center,Boston MA, USA;2-Hopital Beaujon,INSERM UMR 1149 and University of Paris-Diderot,Clichy,France; 3-University of Colorado,Denver,Aurora,CO,USA;4-LiverUnit,IDIBAPS, CIBEREHD, Barcelona, Spain;5-Gilead Sciences Inc,Foster City,CA; 6-Mayo Clinic,Rochester, MN,USA; 7-Auckland University, Auckland,New Zealand. HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment;final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension. EASL International Liver Congress, April 13-17,2016. Barcelona, Spain (Poster Presentation).

G Silva-Junior, F Turon, A Baiges, E Cerda Reyes, L Tellez, V Hernandez-Gea, J Bosch, JC Garcia-Pagan. Standardisation of portal pressure gradients measurements after tips. does it matter? EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Congress presentation).

B Procopet\*, G Silva-Junior, E Llop, A Darnell, MA Garcia-Criado, F Turon, A Baiges, JL Calleja, J Bosch, V Hernandez-Gea, JC Garcia-Pagán, \*Romania. The incidence of rethrombosis in patients with non-cirrhotic, non-tumoral chronic portal vein thrombosis- a prospective observational study. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster Congress presentation).

D Hide , M Ortega-Ribera, A Warren, D Le Couteur, J Bosch, V Cogger, J Gracia-Sancho, Spain Ischemia/reperfusion injury in the aged liver: the importance of the sinusoidal endothelium in developing therapeutic strategies for the elderly. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster Congress presentation).



F Turón(1), A Baiges(1), A Garcia-Criado(2), I Nuñez (2), R Gilabert(2), C Bru(2), A Berzigotti(1), JC Reverter(3), S Seijo(1), J Bosch(1-4), V Hernández-Gea(1-4), JC García-Pagán(1-4).1-Hepatic hemodynamic Laboratory. Liver Unit.IMDM.IDIBAPS; 2-Department of Radiology; 3-Hemotherapy and Hemostasis Unit.Hospital Clinic.Barcelona;4-Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas,CIBERhd, Spain. Portal vein thrombosis in patients with cirrhosis.incidence and factors associated with its development. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster Congress presentation).

AJ Kerbert, E Reverter, L Verbruggen, M Tieleman, M Navasa, M de Vree, HJ Metselaar, FW Chiang, HW Verspaget, B van Hoek, J Bosch, MJ Coenraad\* Netherlands. Hepatic encephalopathy is an independent risk factor for transplant-free survival in patients awaiting liver transplantation. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster Congress presentation).

A Sanyal\*, Z Goodman, S Harrison, DC. Rockey, AM Diehl, S Caldwell, ML Shiffman, P Thuluvath, RP Myers, GM Subramanian, JG McHutchison, MF Abdelmalek, V Ratziu, N Afdhal, J Bosch, United States. Correlation between the hepatic venous pressure gradient and alpha-smooth muscle actin (sma) expression in patients with compensated cirrhosis due to nonalcoholic steatohepatitis. EASL International Liver Congress, April 13-17, 2016. Barcelona, Spain (Poster Congress presentation).

20 anys de recerca en Hemodinàmica hepètica i Hipertensió portal. Auditori Esteve, Edifici CEK-IDIBAPS. IDIBAPS in-house Seminar. Barcelona, Spanien, September 2016 (Special Lecture).

S Lens, E Alvarado-Tapias, Z Mariño, MC Londoño, E Llop, JM González, JI Fortea, L Ibáñez Samaniego, R Bañares, A Puente, AAlbillos, JL Calleja, X Torras, V Hernández-gea, J Bosch, C Villanueva, X Forns, JC García-Pagán. Parallel 8: HCV: Epidemiology and Natural History of HCV I. Impact of all-oral antiviral therapy on portal pressure and hemodynamics on HCV-infected cirrhotic patients. 67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Congress presentation).

F de Mesquita, S Guixé-Muntet, A Fernández-Iglesias, R Maeso-Díaz, D Hide, M Ortega-Ribera,S Vila, J Bosch, JR de Oliveira,J Gracia-Sancho. Parallel 23: Experimental Discoveries in Portal Hypertension and Cirrhosis. Liraglutide de-activates hepatic stellate cells improving liver microvascular dysfunction and fibrosis in rats with chronic liver disease.67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Congress presentation).

V Hernandez-Gea, B Procopet, A Giraldez, L Amitrano, C Villanueva, D Thabut, L Ibañez Samaniego,G Silva-Junior,AAlbillos, J Genesca,C Bureau, J Trebicka, E Llop, W Laleman, JM Palazón, J Castellote,S Rodrigues, LL Gluud, C Noronha Ferreira, N Cañete, C Navascues,A Ferlitsch, JL Mundi,

H Grønbaek, M Hernández Guerra, R Sassatelli, A Dell’Era, M Senzolo, JG Abraldes, M Romero-Gomez, A Zipprich, M Casas, H Masnou, M Primignani, F Torres, A Krag, J Bosch, JC Garcia-Pagán. Parallel 13: Predictors of Outcomes in Cirrhosis Moderators. Early-TIPS improves survival in high-risk variceal bleeders. Results of a Multicenter Variceal Bleeding Observational Study. 67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Congress presentation).

D Pavero, C Johnson, H Yamashita, RP Myers, CS Djedjos, M Subramanian, ZD Goodman, SA Harrison, AJ Sanyal, J Bosch, AE Feldstein. Circulating, hepatocyte-derived extracellular vesicles correlate with fibrosis stage and portal pressure in patients with nonalcoholic steatohepatitis. 67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Congress presentation).

J Gracia-Sancho, P Contreras, S Vila, H Garcia-Caldero, AP Spada, J Bosch. Portal Hypertension Experimental. The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression. 67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Oral Congress presentation).

R Maeso-Díaz, M Ortega-Ribera, A Fernandez-Iglesias, L Muñoz, S Vila, A Albillos, JC Garcia-Pagán, J Bosch, J Gracia-Sancho. Hepatic microcirculatory phenotype in aging: mildly dysfunctional in Health but markedly deteriorated in chronic liver injury. 67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Poster Congress presentation).

JC Garcia-Pagán, A Albillos, G Garcia-Tsao, C Bureau, PE Rautou, Y Llan, J Bosch. Parallel 23: Experimental Discoveries in Portal Hypertension and Cirrhosis. 13C-Methacetin Breath test to assess presence of clinically significant portal hypertension: A novel tool for the management of patients with compensated Advanced chronic liver diseases. 67th Annual Meeting of the AASLD, November 11-14, 2016. Boston, Massachusetts (Oral Congress presentation).

Bosch J. II Jornada Interactiva en el Laboratorio de Hemodinámica Hepática del Hospital Clínic de Barcelona. Ponencia: Tratamiento de la HDA por Varices Esófago-Gástricas Indicaciones del TIPS- Dr. Jaume Bosch. Barcelona, 18 de Octubre de 2016 (Lecture).

Dr. Jaume Bosch, Doctor Honoris Causa por la Universitat Cluj-Napoca (Transilvania) el 24 de Noviembre de 2016. El Dr. Bosch es reconocido por su labor en el campo de la hepatología y concretamente en el análisis de la hipertensión portal y los trastornos hemodinámicos asociados a enfermedades hepáticas.

## **Dr. med. G. Stirnimann**

Alfapump: Experience and Results of the PMSR Study. Mini-symposium alfapump in the Netherlands. Amsterdam, the Netherlands, 26. 01.2016

HCV Treatment – Who do I treat now? Extrahepatic disease. AbbVie Roundtable. Barcelona, Spain, 13.04.2016

The Automated Low Flow Ascites Pump (alfapump). Hôpital Riaz, Riaz. 13.09.2016

Sicherheit und Effizienz der alfaPumpe. Aktuelle Datenlage. Studententreffen AGUA Trial. Frankfurt/Main, Deutschland, 16.09.2016

Nicht-alkoholische Fettlebererkrankung: Harmlos oder gefährlich? Fachtagung Diätetik von der Theorie zur Praxis - Wiederernährung, Lebererkrankungen, Nichtzöliakie-Glutensensitivität. Bern, 04.11.2016

Human Research Act. Good Clinical Practice Course. Bern, 23.11.2016

Design of Clinical Trials. Good Clinical Practice Course. Bern, 23.11.2016

Data Management & Safety Management. Good Clinical Practice Course. Bern, 14.12.2016

Swissmedic & BAG. Good Clinical Practice Course. Bern, 14.12.2016

Clinical Case Discussion. Preceptorship Improving Outcomes in Chronic Liver Disease, Bern, Juni 2016.

## **Dr. med. S. Casu**

Clinical Case Discussion. Preceptorship Improving Outcomes in Chronic Liver Disease. Bern, Juni 2016.

Autoimmune Hepatitis in Liver Transplantation. Donnerstags Fortbildung UVCM 2016.

## **Prof. Dr. Jeff Idle**

Metabolomics in the 21st Century. Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda MD, USA, Dezember 2016.

## **Prof. Dr. em. Marc Solioz**


Antimicrobial copper materials for hygiene and infection prevention - Too good to be true? 4. April 2016. Univ. of Bern, DKF, J.-F. Dufour.

Copper - essential, toxic, magic. 17. Mai. 2016. Univ. of Nizhny Novgorod, Svetlana Pleskova.

Why copper surfaces are antibacterial. 12. Juli 2016. Biometals 2016, Dresden.

Why copper surfaces are antimicrobial. 26. September 2016. Intl. Copper Meeting 2016.

## 4. Klinische Studien



### Aktive Studien

#### Leberkrebs

- Kohortenstudie von Patienten mit HCC, ohne Sponsor, keine Medi, kein Blut, nur Fragebögen.
- BAYER HCC 15982: Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Studie der Phase III zu Regorafenib bei Patienten mit hepatozellärem Karzinom (HCC) nach Sorafenib.
- ARQ 197-A-U303 (METIV-HCC): A phase 3, randomized, double-blind study of Tivantinib (ARQ197) in subjects with MET diagnostic-high inoperable HCC treated with one prior systemic therapy.
- LILLY (REACH 2) I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib” (Lilly).
- BMS HCC CA209-040: Nivolumab, Phase 3: A Randomized, Multi-Center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma.
- HCC Cohort.
- Tissue Factor in HCC.

## Virale Hepatitis

- HBV-Genomics: Human Genomics of Fulminant Hepatitis B Infection.
- GS-US-337-0124: A Phase 2, double blind, randomized study evaluating the safety, tolerability and efficacy of GS-4997 in combination with prednisolon versus prednisolon alone in subjects with severe alcoholic hepatitis
- GS-US-337-0124: A phase 2, multicenter, open-label study to investigate the safety and efficacy of sofosbuvir/ledipasvir fixed-dose combination ribavirin administered in subjects infected with chronic HCV who have advanced liver disease or are post-liver transplant
- Abbvie M14-423: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
- Abbvie M13-590: Endurance I, GNT3 Sof/Riba vs ABT493/ABT530 12 weeks, Genotype 1
- SCCS - Schweizerische Hepatitis C Kohortenstudie mit Hepatitis C Virus Infizierten: Lack of Physical Activity as a Risk Factor for HCC in Patients with chronic Hepatitis C, Analyse von Blutproben gesammelt im Rahmen der SCCSj-Kohortenstudie
- Biotest: A Retrospective Data Collection to Increase the Knowledgebase of Posttransplant Treatment with the Human Hepatitis B Immunoglobulin Zutectra or Hepatect CP in Liver Transplanted Patients.
- Abbvie M 13-594, Endurance 3: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection.
- HCV Cohort: Gender Specific Outcome of HCV Infection in the Swiss HCV Cohort Pregnancy as Protective Factor for Advanced Fibrosis and Predictor of SVR.

## **Metabolische Leberkrankheiten**

- NASH EU FLIP Cohort EU-FLIP Cohort of patients with non-alcoholic steatohepatitis.
- SASL 34 Treatment of non-alcoholic steatohepatitis (NASH) patients with vitamin D. A randomized, double blind, placebo-controlled multicentre phase II trial in patients with fatty liver disease.
- Intercept 747-303 NASH (REGENERATE): A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

## **Zirrhose**

- INFECIR-2: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality SCNTP880
- Genotypic and Phenotypic Characterisation of Albumin in Cirrhotic Patients
- Prosper: Phase IV observational hepatic encephalopathy +/- rifaximin
- NABEL Zirrhosen-Datenbank (Kanada und Bern)

## **Vaskuläre Lebererkrankung**

- SASL 35: Swiss Liver Venous Thrombosis Study: A multicenter prospective observational cohort study
- Quality Assessment in Hepatic Hemodynamic Procedures at Insepsital: Radiation Exposure, Iodine Contrast Use and Procedure Related Complications.

## **Auto-immune Krankheiten**

- Intercept 747-302: A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis (protocol number 747-302).

## **Medikamenten-induzierte Lebererkrankungen**

- Pro-Euro DILI Registry: Creation of a Multicentre and Multidisciplinary European Registry of Prospective Drug-Induced Liver Injury Cases (Pro-Euro-DILI).

## 5. Stiftung für Leberkrankheiten

*(Zweck der Stiftung: Die Stiftung bezweckt die Finanzierung der Forschung sowie der Aus- und Weiterbildung in Diagnostik und Therapie von Leberkrankheiten und zwar im Rahmen des Ordinariats für Hepatologie der Medizinischen Fakultät Bern)*

*Der Stiftungsrat wurde um zwei Personen erweitert. Ab 2017 werden ihm angehören:*

- Prof. Dr. med. Jean-François Dufour, Präsident
- Sébastien Baumann, Rechtsanwalt, Stiftungsrat
- Prof. Dr. med. Dr. phil. nat. Jaime Bosch, Stiftungsrat
- Dr. med. Dr. phil. nat. Ronald H.W. Lorijn, MBA, Stiftungsrat
- Prof. Dr. med. Dr. phil. nat. Nikolai Naoumov, FAASLD, Stiftungsrat
- Prof. em. Dr. med. Jürg Reichen, Stiftungsrat
- Dr. med. Michael Schenk, Stiftungsrat
- Dr. med. Franziska Schöni-Affolter, Stiftungsrätin

Die Stiftung für Leberkrankheiten erhielt auch 2016 wieder Spenden von mehreren privaten Personen.



**30 JAHRE  
FORSCHUNG,  
FORTSCHRITT UND  
INNOVATIVE  
PROJEKTE**

**UNSER ENGAGEMENT  
GEHÖRT  
IHRER ZUKUNFT**



<https://www.swissliver.ch/de/Stiftungen/Stiftung-fuer-Leberkrankheiten>


## 6. Fondation contre le cancer du Foie

(Stiftungszweck:

1. Förderung der Erforschung von Lebertumoren in der Schweiz und im Ausland.
2. Förderung der Entwicklung und Verbesserung der Pflege von Patientinnen und Patienten mit Lebertumoren in der Schweiz und im Ausland.
3. Permanente oder temporäre Aktivitäten in der Schweiz oder im Ausland oder Organisation von Veranstaltungen, welche die Stiftung hinsichtlich der direkten oder indirekten Realisierung ihrer unter 1 und 2 genannten Ziele für nötig erachtet.)

Die 2015 erarbeiteten Strategien zur Mittelbeschaffung fingen 2016 an zu greifen. Der neue Flyer liegt in Arztpraxen und Wartezimmern von Spitälern auf. Seit 1. Oktober 2016 besucht eine Medizinstudentin praktizierende Aerzte und macht sie auf die Stiftung aufmerksam.

Der Preis der Stiftung wurde während des HCC Days in Zürich an Dr. Perparim Limani verliehen für dessen Arbeit: Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.



<https://cancer-du-foie.ch>



## 7. Personelles und Liste der Mitarbeitenden

Das Team der Hepatologischen Kaderärzte umfasste 2016: Prof. Jean-François Dufour als Chefarzt, Prof. Andrea De Gottardi, Prof. Annalisa Berzigotti und PD Dr. Nasser Semmo als Leitende Aerzte, Dr. Stirnimann, Dr. Stefania Casu als Oberärzte, Dres Schwacha-Eipper (neu) und G. Murgia (neu) als Assistenzärzte. Sie wurden in der Poliklinik durch die Assistenzärztinnen und -ärzte M. Knöpfli, C. Margini, M. Schranz, D. Segna, N. Sutter, C. Winkler und H. Zenz, M. Gerbert, N. Geider, C. Keller, unterstützt.

Im Zusammenhang mit klinischen Studien arbeiteten 2016 in der Hepatologie die Dres Nair R. Harikumar und Andrej Hari als Aerzte sowie Dres Sheida Moghadamrad und Isabelle Voegeli als wissenschaftliche Mitarbeiterinnen. Die Studienkoordinatorin, Kathrin Husi, wurde durch die Study Nurses Christine Iannarella, Mirjam Conrad, Jeannine Stricker, Alice Gilg und Patrick Brunner unterstützt. Monique Obertin koordinierte die regulatorische Abwicklung der Studien von der Vertragsprüfung bis zum Ethikvotum. Als Data-Manager/in waren Stefanie Mühlemann und Dr. A. Ayukebi tätig.

PD Dr. Dr. Semmo führte seit Mitte Oktober 2016 die Hepatologische Sprechstunde im Tiefenau.

Pavitra Kumar, Doktorand von Prof. Chatterjee vom AU-KBC Research Centre in Chennai, Indien, besuchte uns für 9 Monate. Er arbeitete am ISJRP (Indo Swiss Joint Research Programm) zum *Thema Nitric oxide in hepatocellular carcinoma: mechanisms and therapeutic implications.*

## Liste der Mitarbeitenden

Aeby Guillaume	Masterstudent
Ayukebi Andreas	wiss. Mitarbeiter
Bélet David	Laborant
Berzigotti Annalisa	Oberärztin
Beyoglu Diren	wiss. Mitarbeiterin
Blaser Elisabeth	Stv. Chefsekretärin
Bosch Jaime	Gastprofessor
Bracher Selin	Med. Praxisassistentin
Brunner Felix	Stv. Oberarzt
Brunner Patrick	Study Nurse
Bühlmann Stefanie	Med. Praxisassistentin
Casu Stefania	Oberärztin
Caversaccio Nathalie	Masterstudentin
Conrad Mirjam	Study Nurse
Cornels Angelika	Chefsekretärin
De Gottardi Andrea	Leitender Arzt
De Gottardi Jacqueline	Doktorandin
Dufour Jean-François	Chefarzt
Gilg Alice	Study Nurse
Gisler Lisa	Datamanagerin
Gmür Andrea	Doktorandin (MD)
Gonzalez Martin	Mitarbeiter Reinigungsdienst
Gstrein Nathalie	Masterarbeit (MD)
Hari Andrej	Gastarzt
Heller Selina	Med. Praxisassistentin
Husi Kathrin	Studienkoordinatorin
Iannarella Christine	Study Nurse
Idle Jeffrey	Gastprofessor
Keller Salome	Masterstudentin
Kellmann Philipp	Laborant
Knoepfli Marina	Assistenzärztin
Kolly Philippe	Masterstudent
Korovnikova Natalia	Datamanagerin
Kumar Pavitra	Doktorand
Lacalamita Stefan	Sachbearb. Rechnungswesen
Liechti Fabia	Masterstudentin
Lokhande Megha U	Post-Doktorandin
Matthia Odai	Doktorand

Maurer Dominique	Sekretärin
Maurhofer Olivier	Cheflaborant
Moghadamrad Sheida	Post-Doktorandin
Mühlemann Stefanie	Datamanagerin
Nahmias Silvio	Doktorand (MD)
Nair R. Harikumar	Gastarzt
Ndarugendamwo Angelique	Masterstudentin (MD)
Obertin Monique	Sekretariatsleiterin Forschung
Prillmann Anna	Mitarbeiterin Reinigungsdienst
Prillmann Fabian	Mitarbeiter Reinigungsdienst
Rajasekaran Raviprasadh	Doktorand
Ricardo Maria	Mitarbeiterin Reinigungsdienst
Rodriguez Navarro Sarai	Gast-Doktorandin
Saran Uttara	Post-Doktorandin
Schranz Melanie	Assistenzärztin
Semmo Nasser	Leitender Arzt
Smith Lilian	Sekretärin
Stirnemann Guido	Oberarzt
St-Pierre Marie	wiss. Mitarbeiterin
Straub Monica	Mitarbeiterin Hausdienst
Stricker Jeannine	Study Nurse
Sutter Nora	Assistenzärztin
Traschitzger Michaela	Assistenzärztin
Voegeli Isabelle	wiss. Mitarbeiterin
Volkova Ekaterina	wiss. Mitarbeiterin
von Köckritz Leona	Doktorandin (MD)
Walid Ibrahim	Doktorand (MD)
Weber Thomas	Laborant
Winkler Carmen	Assistenzärztin
Ziegler Chiara	Med. Praxisassistentin
Zenz Heike	Assistenzärztin



Laboratory Murstenstraat 35



## 8. Verzeichnis der Drittmittel 2016

### SNF Kredite

Verantwortliche Person	Nummer	Beginn	Ende
J.-F. Dufour	31003A-140930	01.04.2015	31.03.2018
J.-F. Dufour	CRSII3-141798/1	01.01.2016	31.12.2018
J.-F. Dufour	IZLIZ3-156447	01.01.2015	31.12.2017
A. Berzigotti	UniBe-ID Grant	01.01.2016	28.02.2018
A. De Gottardi	31003A-163143	01.11.2015	31.10.2018

### Übrige Drittmittel

Verantwortliche Person	Sponsor	Gebiet
J.-F. Dufour	(Kohorte PI F. Negro)	Hepatitis C Kohorte
J.-F. Dufour	Kohorte	
J.-F. Dufour	CCI779	Diverse
N. Semmo	W. und G. Siegenthaler Stiftung	Immunopathogenesis of hepatitis C virus infection CD4* T cell failure in chronic HCV infection
J.-F. Dufour	Krebsforschung Schweiz	How physical activity influences carcinogenesis: the case of HCC
J.-F. Dufour	Inselspital	Guest Professorship

Verantwortliche Person	Sponsor	Gebiet
A. De Gottardi	Sequana	Automatische Entfernung überschüssiger Peritonealflüssigkeit in die Harnblase bei Patienten mit Zirrhose und mit persistentem refraktärem Aszites



## 9. Uebersicht Lehrleistungen 2016

**Die folgenden Personen beteiligten sich im Berichtsjahr an der Lehre:**

Prof. Jean-François Dufour  
Prof. Andrea De Gottardi  
Prof. Annalisa Berzigotti  
Prof. Jeff Idle  
PD Nasser Semmo  
Dr. Guido Stirnimann  
Dr. Stefania Casu  
Dr. Diren Beyoglu  
Dr. Sheida Moghadamrad  
Dr. Uttara Saran

## 10. Publikationen

### Prof. Dr. med. J.-F. Dufour

1. Herrmann, Evelyn; Naehrig, Diana; Sassowsky, Manfred; Bigler, Martin; Buijsen, Jeroen; Ciernik, Ilja; Zwahlen, Daniel; Pellanda, Alessandra Franzetti; Meister, Andreas; Brauchli, Peter; Berardi, Simona; Kuettel, Erika; Dufour, Jean-François; Aebersold, Daniel; Swiss Group for Clinical Cancer Research (SAKK) (2017). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. *Radiation oncology* (London, England), 12(1), p. 12. 10.1186/s13014-016-0745-0
2. Dufour, Jean-François (2017). *Hepatology Highlights*. *Hepatology* (Baltimore, Md.), 65(1), pp. 1-3. 10.1002/hep.28935
3. Hari, Andrej; Nair, Harikumar; De Gottardi, Andrea; Baumgartner, Iris; Dufour, Jean-François; Berzigotti, Annalisa (2017). Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. *Liver international : official journal of the International Association for the Study of the Liver*, 37(1), pp. 148-154. 10.1111/liv.13215
4. Kolly, Philippe; Dufour, Jean-François (2016). Patients with hepatocellular carcinoma: Your address matters! (In Press). *Journal of hepatology* 10.1016/j.jhep.2016.11.026
5. Dufour, Jean-François (2016). *Hepatology Highlights*. *Hepatology* (Baltimore, Md.), 64(6), pp. 1829-1830. 10.1002/hep.28867
6. von Köckritz, Leona Isabella; Dufour, Jean-François (2016). Management of chronic hepatitis C in 2017. *Hamostaseologie*, 37(1) 10.5482/HAMO-16-07-0019
7. Dufour, Jean-François (2016). *Hepatology Highlights*. *Hepatology* (Baltimore, Md.), 64(5), pp. 1395-1397. 10.1002/hep.28828
8. Maan, Rael; Zaim, Remziye; van der Meer, Adriaan J; Feld, Jordan J; Wedemeyer, Heiner; Dufour, Jean-François; Lammert, Frank; Manns, Michael P; Zeuzem, Stefan; Hansen, Bettina E; Janssen, Harry LA; Veldt, Bart J; de Knegt, Robert J; Uyl-de Groot, Carin A (2016). Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. *Journal of gastroenterology and hepatology*, 31(11), pp. 1851-1859. 10.1111/jgh.13373
9. Martin, Juliette; Balmer, Maria Luisa; Rajendran, Saranya; Maurhofer, Olivier; Dufour, Jean-François; St-Pierre Dufour, Marie Vivien (2016). Nutritional stress exacerbates hepatic steatosis induced by deletion of the histidine nucleotide-binding (Hint2) mitochondrial protein. *American journal of physiology. Gastrointestinal and liver physiology*, 310(7), G497-509. 10.1152/ajpgi.00178.2015
10. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. (In Press). *The American journal of gastroenterology* 10.1038/ajg.2016.453

11. Perazzo, Hugo; Dufour, Jean-François (2016). The therapeutic landscape of non-alcoholic steatohepatitis. (In Press). *Liver international : official journal of the International Association for the Study of the Liver* 10.1111/liv.13270
12. Dufour, Jean-François (2016). *Hepatology Highlights*. *Hepatology* (Baltimore, Md.), 64(4), pp. 1011-1013. 10.1002/hep.28764
13. Giudici, F; Bertisch, B; Negro, F; Stirnimann, G; Müllhaupt, B; Moradpour, D; Cerny, A; Dufour, Jean-François; Keiser, O (2016). Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. *Journal of viral hepatitis*, 23(9), pp. 697-707. Blackwell Science 10.1111/jvh.12535
14. Teufel, Andreas; Itzel, Timo; Erhart, Wiebke; Brosch, Mario; Wang, Xiao Yu; Kim, Yong Ook; von Schönfels, Witigo; Herrmann, Alexander; Brückner, Stefan; Stickel, Felix; Dufour, Jean-François; Chavakis, Triantafyllos; Hellerbrand, Claus; Spang, Rainer; Maass, Thorsten; Becker, Thomas; Schreiber, Stefan; Schafmayer, Clemens; Schuppan, Detlef and Hampe, Jochen (2016). Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. *Gastroenterology*, 151(3), 513-525.e0. 10.1053/j.gastro.2016.05.051
15. Linecker, Michael; Limani, Perparim; Kambakamba, Patryk; Kron, Philipp; Tschuur, Christoph; Calo, Nicolas; Foti, Michelangelo; Dufour, Jean-François; Graf, Rolf; Humar, Bostjan; Clavien, Pierre-Alain (2016). Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy. *Annals of surgery*, p. 1. 10.1097/SLA.0000000000001968
16. Dufour, Jean-François (2016). *Hepatology Highlights*. *Hepatology*, 64(3), pp. 703-705. Wiley Interscience 10.1002/hep.28725
17. Tapper, Elliot B; Hughes, Michael S; Buti, Maria; Dufour, Jean-François; Flamm, Steve; Firdoos, Saima; Curry, Michael P; Afdhal, Nezam H (2016). The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. *Transplantation*, p. 1. 10.1097/TP.0000000000001400
18. Teufel, Andreas; Dufour, Jean-François (2016). Two-Step Forward Genetic Screen in Mice Identifies the Ral Pathway as a Central Drug Target in Hepatocellular Carcinoma. *Gastroenterology*, 151(2), pp. 231-233. Elsevier 10.1053/j.gastro.2016.06.034
19. Zeuzem, Stefan; Mantry, Parvez; Soriano, Vicente; Buynak, Robert J; Dufour, Jean-François; Pockros, Paul J; Wright, David; Angus, Peter; Buti, Maria; Stern, Jerry O; Kadus, Werner; Vinisko, Richard; Böcher, Wulf; Mensa, Federico J (2016). Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. *European journal of gastroenterology & hepatology*, 28(8), pp. 923-926. 10.1097/MEG.0000000000000649
20. Dufour, Jean-François (2016). *Hepatology Highlights*. *Hepatology*, 64(2), pp. 325-327. Wiley Interscience 10.1002/hep.28683
21. Zahnd, Cindy; Salazar-Vizcaya, Luisa; Dufour, Jean-François; Müllhaupt, Beat; Wandeler, Gilles; Kouyos, Roger; Estill, Janne; Bertisch, Barbara; Rauch, Andri;

- Keiser, Olivia (2016). Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. *Journal of hepatology*, 65(1), pp. 26-32. Elsevier 10.1016/j.jhep.2016.02.030
22. Diserens, Gaëlle; Vermathen, Martina; Lévy, P; Dufour, J-F; Vermathen, Peter; Bartosch, B (27 June 2016). NMR spectroscopy detects metabolite differences between culture media of hepatitis C virus negative and positive cells after harvest. In: 12th Annual Conference of the Metabolomics Society. Dublin, Ireland. 27.-30.06.2016.
  23. Dufour, Jean-François (2016). *Hepatology Highlights*. *Hepatology*, 64(1), pp. 1-3. Wiley Interscience 10.1002/hep.28645
  24. Manns, Michael; Samuel, Didier; Gane, Edward J; Mutimer, David; McCaughan, Geoff; Buti, Maria; Prieto, Martín; Calleja, José Luis; Peck-Radosavljevic, Markus; Müllhaupt, Beat; Agarwal, Kosh; Angus, Peter; Yoshida, Eric M; Colombo, Massimo; Rizzetto, Mario; Dvory-Sobol, Hadas; Denning, Jill; Arterburn, Sarah; Pang, Phillip S; Brainard, Diana; ... (2016). Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. *The Lancet. Infectious diseases*, 16(6), pp. 685-697. 10.1016/S1473-3099(16)00052-9
  25. Calo, Nicolas; Ramadori, Pierluigi; Sobolewski, Cyril; Romero, Yannick; Maeder, Christine; Fournier, Margot; Rantakari, Pia; Zhang, Fu-Ping; Poutanen, Matti; Dufour, Jean-François; Humar, Bostjan; Nef, Serge; Foti, Michelangelo (2016). Stress-activated miR-21/miR-21\* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. *Gut*, 65(11), pp. 1871-1881. 10.1136/gutjnl-2015-310822
  26. Dufour, Jean-François (2016). *Hepatology highlights*. *Hepatology*, 63(6), pp. 1749-1751. Wiley Interscience 10.1002/hep.28605
  27. Koeberle, D; Dufour, Jean-François; Demeter, G; Li, Q; Ribi, K; Samaras, P; Saletti, P; Roth, A D; Horber, D; Bühlmann, Michael; Wagner, A D; Montemurro, M; Lakatos, G; Feilchenfeldt, J; Peck-Radosavljevic, M; Rauch, D; Tschanz, B; Bodoky, G; Swiss Group for Clinical Cancer, SAKK (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). *Annals of oncology : official journal of the European Society for Medical Oncology*, 27(5), pp. 856-861. 10.1093/annonc/mdw054
  28. Dufour, Jean-François (2016). *Hepatology highlights*. *Hepatology*, 63(5), pp. 1405-1407. Wiley Interscience 10.1002/hep.28566
  29. Martin, Juliette; Balmer, Maria Luisa; Rajendran, Saranya; Maurhofer, Olivier; Dufour, Jean-François; St-Pierre Dufour, Marie Vivien (2016). Nutritional stress exacerbates hepatic steatosis induced by deletion of the histidine nucleotide-binding (Hint2) mitochondrial protein. *American journal of physiology. Gastrointestinal and liver physiology*, 310(7), G497-509. 10.1152/ajpgi.00178.2015
  30. Dufour, Jean-François (2016). *Hepatology highlights*. *Hepatology*, 63(4), pp. 1065-1067. Wiley Interscience 10.1002/hep.28498



31. Foster, G R; Ferenci, P; Asselah, T; Mantry, P; Dufour, Jean-François; Dufour, Jean-François; Bourlière, M; Forton, D; Maevskaia, M; Wright, D; Yoshida, E M; García-Samaniego, J; Oliveira, C; Wright, M; Warner, N; Sha, N; Quinson, A-M; Stern, J O (2016). Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. *Journal of viral hepatitis*, 23(3), pp. 227-231. Blackwell Science 10.1111/jvh.12485
32. Margini, Cristina; Dufour, Jean-François (2016). The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. *Liver international*, 36(3), pp. 317-324. Blackwell Munksgaard 10.1111/liv.13031
33. Dufour, Jean-François (2016). Hepatology highlights. *Hepatology*, 63(3), pp. 679-681. Wiley Interscience 10.1002/hep.28454
34. Dufour, Jean-François (2016). Hepatology highlights. *Hepatology*, 63(2), pp. 351-353. Wiley Interscience 10.1002/hep.28402
35. Dufour, Jean-François (2016). Time to Abandon NASH? *Hepatology*, 63(1), pp. 9-10. Wiley Interscience 10.1002/hep.28276
36. Saran, Uttara; Humar, Bostjan; Kolly, Philippe; Dufour, Jean-François (2016). Hepatocellular carcinoma and lifestyles. *Journal of hepatology*, 64(1), pp. 203-214. Elsevier 10.1016/j.jhep.2015.08.028
37. Bechtel-Grosch, Ursina; Béguelin, Charles Antoine; Berezowska, Sabina Anna; Dufour, Jean-François; Takala, Jukka; Schefold, Joerg C. (2016). Fulminant hepatic and multiple organ failure following acute viral tonsillitis: a case report. *Journal of medical case reports*, 10(7), p. 7. BioMed Central 10.1186/s13256-015-0777-3
38. Kolly, Philippe; Dufour, Jean-François (2016). Reply to «Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts)». *Journal of hepatology*, 65(6), pp. 1268-1269. Elsevier 10.1016/j.jhep.2016.07.032
39. Kolly, Philippe; Dufour, Jean-François (2016). Surveillance for Hepatocellular Carcinoma in Patients with NASH. *Diagnostics*, 6(2), p. 22. MDPI 10.3390/diagnostics6020022
40. Lévy, Pierre L.; Duponchel, Sarah; Eischeid, Hannah; Molle, Jennifer; Michelet, Maud; Diserens, Gaëlle; Vermathen, Martina; Vermathen, Peter; Dufour, Jean-François; Dienes, Hans-Peter; Steffen, Hans-Michael; Odenthal, Margarete; Zoulim, Fabien; Bartosch, Birke (2016). Hepatitis C virus infection triggers a tumor-like glutamine metabolism (In Press). *Hepatology Wiley Interscience* 10.1002/hep.28949
41. Munteanu, M.; Tiniakos, D.; Anstee, Q.; Charlotte, F.; Marchesini, G.; Bugianesi, E.; Trauner, M.; Romero Gomez, M.; Oliveira, C.; Day, C.; Dufour, Jean-François; Bellentani, S.; Ngo, Y.; Traussnig, S.; Perazzo, H.; Deckmyn, O.; Bedossa, P.; Ratziu, V.; Poynard, T. (2016). Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. *Alimentary Pharmacology & Therapeutics*, 44(8), pp. 877-889. 10.1111/apt.13770

42. Scherer, Antonia; Dufour, Jean-François (2016). Treatment of Non-Alcoholic Fatty Liver Disease. *Digestive diseases* (Basel, Switzerland), 34 Suppl 1, pp. 27-31. 10.1159/000447278
43. *Abstracts*
44. Llovet, J; Merle, P; Weiss, KH; Yau, T; Ross, P; Mazzaferro, V; Blanc, JF; Ma, Y; Yen, C; Kocsis, J; Choo, S; Sukeepaisarnjaroen, W; Gerolami, R; Dufour, Jean-François; Gane, E; Ryoo, BY; Peck, M; Dao, T; Yeo, W; Lamlertthon, W; ... (November 2016). Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC). Supplement to *Hepatology*, 64(1), 621A-621A. AASLD
45. Munteanu, M.; Tiniakos, D.; Anstee, Q.; Charlotte, F.; Marchesini, G.; Bugianesi, E.; Trauner, M.; Oliveira, C.; Day, C.; Dufour, Jean-François; Bellentani, S.; Ngo, Y.; Traussnig, S.; Bedossa, P.; Ratziu, V.; Poynard, T. (November 2016). Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Supplement to *Hepatology*, 64(1), 585A-585A.

**Prof. Dr. med. Dr. phil. nat. Andrea De Gottardi**

46. Alcaraz-Quiles, José; Titos, Esther; Casulleras, Mireia; Pavesi, Marco; López-Vicario, Cristina; Rius, Bibiana; Lopategi, Aritz; De Gottardi, Andrea; Graziadei, Ivo; Gronbaek, Henning; Ginès, Pere; Bernardi, Mauro; Arroyo, Vicente; Clària, Joan (2017). Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. *Hepatology* (Baltimore, Md.), 65(1), pp. 202-216. 10.1002/hep.28896
47. De Gottardi, Andrea; Trebicka, Jonel; Klinger, Christoph; Plessier, Aurélie; Seijo, Susana; Terziroli, Benedetta; Magenta, Lorenzo; Semela, David; Buscarini, Elisabetta; Langlet, Philippe; Görtzen, Jan; Puente, Angela; Müllhaupt, Beat; Navascuès, Carmen; Nery, Filipe; Deltenre, Pierre; Turon, Fanny; Engelmann, Cornelius; Arya, Rupen; Caca, Karel; ... (2016). Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. (In Press). *Liver international : official journal of the International Association for the Study of the Liver* 10.1111/liv.13285
48. Heimgartner, B; Dawson, Heather; De Gottardi, Andrea; Niess, Jan Hendrik (2016). Successful Treatment of Small Intestinal Bleeding in a Crohn's Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment. *Case Rep Gastroenterol*.
49. Heimgartner, Benjamin; Dawson, Heather; De Gottardi, Andrea; Wiest, Reiner; Niess, Jan Hendrik (2016). Successful Treatment of Small Intestinal Bleeding in a Crohn's Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment. *Case reports in gastroenterology*, 10(3), pp. 589-595. Karger 10.1159/000450541
50. Clària, Joan; Stauber, Rudolf E; Coenraad, Minneke J; Moreau, Richard; Jalan, Rajiv; Pavesi, Marco; Amorós, Alex; Titos, Esther; Alcaraz-Quiles, José; Oettl, Karl; Morales-Ruiz, Manuel; Angeli, Paolo; Domenicali, Marco; Alessandria, Carlo;

Gerbes, Alexander; Wendon, Julia; Nevens, Frederik; Trebicka, Jonel; Laleman, Wim; Saliba, Faouzi; ... (2016). Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. *Hepatology* (Baltimore, Md.), 64(4), pp. 1249-1264. 10.1002/hep.28740

51. De Gottardi, Andrea; Greenslade, Lynda C M; Walker, Margaret A (2016). Hepatic encephalopathy: A call to action to optimize patient outcomes. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*, 48(7), pp. 820-822. 10.1016/j.dld.2016.03.030
52. Aebi-Popp, Karoline; Duppenhaler, Andrea; Rauch, Andri; De Gottardi, Andrea; Kahlert, Christian (2016). Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. *Journal of virus eradication*, 2(1), pp. 52-54. Mediscript
53. Trebicka, J; De Gottardi, Andrea; Dell'Era, A; Leebeek, F; Sarin, S; Seijo, S; Valla, D; Primignani, M (2016). Session 6: Consensus Statements – Vascular Diseases of the Liver in Cirrhotic and Noncirrhotic Portal Hypertension. In: *Portal Hypertension VI* (pp. 421-426). Springer 10.1007/978-3-319-23018-4
54. De Gottardi, Andrea; Berg, Thomas; Bernardi, M; Berzigotti, Annalisa; Bureau, C; Caca, K; Engelmann, C; Jalan, Rajiv; Klingler, C; Laurent, J; Macdonald, S; Müller, N; Stirnimann, Jessica; Stirnimann, Guido; Zaccherini, G (2016). Management of cirrhotic patients with ascites 1. *Uni-Med Science*

### **Prof. Dr. med. Dr. phil. nat. A. Berzigotti**

55. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology*. 2016 Oct 27. doi: 10.1002/hep.28906. [Epub ahead of print] PMID: 27786365
56. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, Procopet B, Bosch J, Genesca J, Berzigotti A; Anticipate Investigators. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The „Anticipate“ study. *Hepatology*. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. PMID: 27639071
57. Hari A, Nair HK, De Gottardi A, Baumgartner I, Dufour JF, Berzigotti A. Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. *Liver Int*. 2016 Aug 6. doi: 10.1111/liv.13215. [Epub ahead of print] PMID: 27495217
58. Thiele M, Madsen BS, Procopet B, Hansen JF, Møller LM, Detlefsen S, Berzigotti A, Krag A. Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. *Ultraschall Med*. 2016 Jun 7. [Epub ahead of print] PMID: 27273177
59. Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. *Expert Opin Emerg Drugs*. 2016 Jun;21(2):167-81. doi: 10.1080/14728214.2016.1184647.

60. Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, Rodriguez M, Castellote J, García-Pagán JC, Torres F, Calleja JL, Albillos A, Bosch J; BLEPS Study Group (A. Berzigotti). Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. *Gastroenterology*. 2016 May;150(5):1160-1170.e3. doi: 10.1053/j.gastro.2016.01.004.
61. Berzigotti A, Bosch J. Editorial: increased cardiac output in cirrhosis - non-invasive assessment of regional blood flow by magnetic resonance angiography. *Aliment Pharmacol Ther*. 2016 Jun;43(12):1340-2. doi: 10.1111/apt.13615. PMID: 27166983
62. Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. *Hepatology*. 2016 Mar;63(3):1026-40. doi: 10.1002/hep.28132. PMID: 26313307
63. Brunner, Felix; Berzigotti, Annalisa; Bosch, Jaime (2017). Prevention and treatment of variceal haemorrhage in 2017. *Liver international : official journal of the International Association for the Study of the Liver*, 37 Suppl 1, pp. 104-115. 10.1111/liv.13277
64. Garcia-Tsao, Guadalupe; Abraldes, Juan G; Berzigotti, Annalisa; Bosch, Jaime (2017). Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology (Baltimore, Md.)*, 65(1), pp. 310-335. 10.1002/hep.28906
65. Hari, Andrej; Nair, Harikumar; De Gottardi, Andrea; Baumgartner, Iris; Dufour, Jean-François; Berzigotti, Annalisa (2017). Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. *Liver international : official journal of the International Association for the Study of the Liver*, 37(1), pp. 148-154. 10.1111/liv.13215
66. Berzigotti, Annalisa; Albillos, Agustín; Villanueva, Candid; Genescá, Joan; Ardevol, Alba; Augustín, Salvador; Calleja, Jose Luis; Bañares, Rafael; García-Pagán, Juan Carlos; Mesonero, Francisco; Bosch, Jaime; Ciberehd SportDiet Collaborative Group, . (2016). Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study. (In Press). *Hepatology (Baltimore, Md.)* 10.1002/hep.28992
67. Margini, Cristina; Berzigotti, Annalisa (2016). Portal vein thrombosis: The role of imaging in the clinical setting. (In Press). *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 10.1016/j.dld.2016.11.013
68. Abraldes, Juan G; Bureau, Christophe; Stefanescu, Horia; Augustin, Salvador; Ney, Michael; Blasco, Hélène; Procopet, Bogdan; Bosch, Jaime; Genesca, Joan; Berzigotti, Annalisa; Anticipate Investigators, . (2016). Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The „Anticipate“ study. *Hepatology (Baltimore, Md.)*, 64(6), pp. 2173-2184. 10.1002/hep.28824
69. Women in Hepatology Group, The; Berzigotti, Annalisa; Women in Hepatology Group, The (2016). AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 48(8), pp. 860-868. 10.1016/j.dld.2016.04.009

70. Thiele, M; Madsen, B S; Procopet, B; Hansen, J F; Møller, L M S; Detlefsen, S; Berzigotti, Annalisa; Krag, A (2016). Erratum: Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. (In Press). *Ultraschall in der Medizin* (Stuttgart, Germany : 1980) 10.1055/s-0035-1567110
71. Thiele, M; Madsen, B S; Procopet, B; Hansen, J F; Møller, L M S; Detlefsen, S; Berzigotti, Annalisa; Krag, A (2016). Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. (In Press). *Ultraschall in der Medizin* (Stuttgart, Germany : 1980) 10.1055/s-0042-108431
72. Berzigotti, Annalisa; Bosch, Jaime (2016). Editorial: increased cardiac output in cirrhosis - non-invasive assessment of regional blood flow by magnetic resonance angiography. *Alimentary pharmacology & therapeutics*, 43(12), pp. 1340-1342. 10.1111/apt.13615
73. Nair, Harikumar; Berzigotti, Annalisa; Bosch, Jaime (2016). Emerging therapies for portal hypertension in cirrhosis. *Expert opinion on emerging drugs*, 21(2), pp. 167-181. 10.1080/14728214.2016.1184647
74. Abrales, Juan G; Villanueva, Candid; Aracil, Carles; Turnes, Juan; Hernandez-Guerra, Manuel; Genesca, Joan; Rodriguez, Manuel; Castellote, Jose; Garcia-Pagan, Juan Carlos; Torres, Ferran; Calleja, Jose Luis; Albillos, Agustin; Berzigotti, Annalisa; Bosch, Jaime; BLEPS Study Group, The (2016). Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. *Gastroenterology*, 150(5), 1160-1170.e3. 10.1053/j.gastro.2016.01.004
75. Berzigotti, Annalisa (2016). Non-invasive assessment of portal hypertension. *Leading opinions - Innere Medizin*(2/2016), pp. 64-67. *Universimed*
76. Berzigotti, Annalisa; Boyer, Thomas D.; Castera, Laurent; Pinzani, Massimo; de Franchis, Roberto; Genesca, Joan (2016). Consensus Statements: Session 1 - Screening and Surveillance. In: de Franchis, Roberto (ed.) *Portal Hypertension VI. Proceedings of the Sixth Baveno Consensus Workshop: Stratifying Risk and Individualizing Care* (pp. 77-80). Cham: Springer 10.1007/978-3-319-23018-4\_9
77. Bogdan, Procopet; Berzigotti, Annalisa (2016). Results of the Questionnaire. In: de Franchis, Roberto (ed.) *Portal Hypertension VI. Proceedings of the Sixth Baveno Consensus Workshop: Stratifying Risk and Individualizing Care* (pp. 31-37). Cham: Springer 10.1007/978-3-319-23018-4\_4
78. De Gottardi, Andrea; Berg, Thomas; Bernardi, M; Berzigotti, Annalisa; Bureau, C; Caca, K; Engelmann, C; Jalan, Rajiv; Klingler, C; Laurent, J; Macdonald, S; Müller, N; Stirnimann, Jessica; Stirnimann, Guido; Zaccherini, G (2016). Management of cirrhotic patients with ascites 1. *Uni-Med Science*

**Prof. Dr. med. J. Bosch**

79. Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A, Mejias M, Bava FA, Angulo-Urarte A, Graupera M, Navarro P, Bosch J, Fernandez M, Mendez R. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. *Gastroenterology*. 2016 Apr;150(4):982-97.e30. doi: 10.1053/j.gastro.2015.11.038.
80. Abrales JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, Rodriguez M, Castellote J, García-Pagán JC, Torres F, Calleja JL, Albillos A, Bosch J. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterology*. 2016 May;150(5):1160-1170.e3. doi: 10.1053/j.gastro.2016.01.004
81. Garcia-Pras E, Gallego J, Coch L, Mejias M, Fernandez-Miranda G, Pardo R, Bosch J, Mendez R, Fernandez M. Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension. *Gut*. 2016 Mar 16. pii: gutjnl-2015-311157. doi: 10.1136/gutjnl-2015-311157.PMID: 26984852
82. Hide D, Ortega-Ribera M, Garcia-Pagan JC, Peralta C, Bosch J, Gracia-Sancho J. Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. *Sci Rep*. 2016 Feb 24;6:22107. doi: 10.1038/srep22107.
83. Bosch J, Sauerbruch T. Esophageal varices: Stage-dependent treatment algorithm. *J Hepatol*. 2016 Mar;64(3):746-8. doi: 10.1016/j.jhep.2015.11.039. Epub 2016 Jan 19. PMID: 26810377
84. Cerini F, Vilaseca M, Lafoz E, García-Irigoyen O, García-Calderó H, Tripathi DM, Avila M, Reverter JC, Bosch J, Gracia-Sancho J, García-Pagán JC. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. *J Hepatol*. 2016 Apr;64(4):834-42. doi: 10.1016/j.jhep.2015.12.003. Epub 2015 Dec 11.
85. Guixé-Muntet S, de Mesquita FC, Vila S, Hernandez-Gea V, Peralta C, García-Pagán JC, Bosch J, Gracia-Sancho J. Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. *J Hepatol*. 2016 Aug 18. pii: S0168-8278(16)30433-0. doi: 10.1016/j.jhep.2016.07.051.
86. Bosch J. EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann. *J Hepatol*. 2016 May;64(5):996-7. doi: 10.1016/j.jhep.2015.12.014. No abstract available. PMID: 27083767
87. Shneider BL, de Ville de Goyet J, Leung DH, Srivastava A, Ling SC, Duché M, McKiernan P, Superina R, Squires RH, Bosch J, Groszmann R, Sarin SK, de Franchis R, Mazariegos GV. Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium. *Hepatology*. 2016 Apr;63(4):1368-80. doi: 10.1002/hep.28153. Review.

88. Noronha Ferreira C, Seijo S, Plessier A, Silva-Junior G, Turon F, Rautou PE, Baiges A, Bureau C, Bosch J, Hernández-Gea V, Valla D, García-Pagan JC. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. *Hepatology*. 2016 May;63(5):1640-50. doi: 10.1002/hep.28466. Epub 2016 Mar 10.
89. Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, Garcia-Pagán JC, Bosch J; Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. *Hepatology*. 2016 Jun;63(6):1957-67. doi: 10.1002/hep.28360. Epub 2016 Jan 14.
90. D'Amico G, Malizia G, Bosch J. Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension? *Hepatology*. 2016 Jun;63(6):1771-3. doi:10.1002/hep.28502. Epub 2016 Mar 22.
91. Villanueva C, Albillos A, Genescà J, Abraldes JG, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Garcia-Pagan JC, Pavel O, Bosch J. Development of hyperdynamic circulation and response to  $\beta$ -blockers in compensated cirrhosis with portal hypertension. *Hepatology*. 2016 Jan;63(1):197-206. doi: 10.1002/hep.28264.
92. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, Procopet B, Bosch J, Genesca J, Berzigotti A; Anticipate Investigators.
93. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The „Anticipate“ study. *Hepatology*. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. PMID:27639071
94. Berzigotti A, Albillos A, Villanueva C, Genescà J, Ardevol A, Augustín S, Calleja JL, Bañares R, García-Pagán JC, Mesonero F, Bosch J; Ciberehd SportDiet Collaborative Group. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. *Hepatology*. 2016 Dec 20. doi: 10.1002/hep.28992. [Epub ahead of print] PMID:27997989
95. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. PMID: 27786365
96. Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. *Expert Opin Emerg Drugs*. 2016 Jun;21(2):167-81. doi:10.1080/14728214.2016.1184647. Epub 2016 May 23.
97. Berzigotti A, Bosch J. Editorial: increased cardiac output in cirrhosis - non-invasive assessment of regional blood flow by magnetic resonance angiography. *Aliment Pharmacol Ther*. 2016 Jun;43(12):1340-2. doi: 10.1111/apt.13615. No abstract available. PMID: 27166983
98. Bosch J, García-Pagán JC. Calculating hepatic venous pressure gradient: Feel free to stay free. *J Vasc Interv Radiol*. 2016 Aug;27(8):1138-9. doi: 10.1016/j.jvir.2016.03.048..
99. Meireles CZ, Pazarin M, Lozano JJ, García-Calderó H, Gracia-Sancho J, García-Pagán JC, Bosch J, Abraldes JG. Simvastatin attenuates liver injury in rodents

- with biliary cirrhosis submitted to hemorrhage/resuscitation. *Shock*. 2016 Aug 24. [Epub ahead of print] PMID: 27559696
100. Seijo S, Lozano JJ, Alonso C, Miquel R, Berzigotti A, Reverter E, Turon F, Martínez-Chantar ML, Castro A, Mato JM, Hernández-Gea V, Bosch J, García-Pagán JC. Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension. *Liver Int*. 2016 Jul;36(7):1051-8. doi: 10.1111/liv.12972. PMID: 26394550
  101. Bosch J. EUS-guided intrahepatic portosystemic shunt: A real alternative to transjugular intrahepatic portosystemic shunt? *Gastrointest Endosc*. 2017 Jan;85(1):248-249. doi: 10.1016/j.gie.2016.08.039. PMID: 27986115
  102. Embade N, Mariño Z, Diercks T, Cano A, Lens S, Cabrera D, Navasa M, Falcón-Pérez JM, Caballería J, Castro A, Bosch J, Mato JM, Millet O. Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum <sup>1</sup>H-NMR Spectroscopy. *PLoS One*. 2016 May 9;11(5):e0155094. doi: 10.1371/journal.pone.0155094. PMID: 27158896
  103. Bosch J. Improving in-hospital management of decompensated cirrhosis in real world settings by a "care bundle": hope, frustration, and lessons to learn. *Alim. Pharm. Ther*. 2016 (in press)
  104. Bosch, Jaime; Gracia-Sancho, J (2016). Session 3: Consensus Statements –New Targets in Therapy: Statins, Antioxidants and Antiangiogenic Strategies. In: Portal Hypertension VI (pp. 127-134). Springer 10.1007/978-3-319-23018-4
  105. Bosch, Jaime; Bañares, R; Hernandez-Gea, V; Peck-Radosavljevic, M; Tsochatzis, E; Zipprich, A; Laleman, W (2016). Session 3: Consensus Statements: Session 2—Impact of Etiological and Anti-fibrotic Therapy . In: Portal Hypertension VI (pp. 135-138). Springer 10.1007/978-3-319-23018-4
  106. Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. *Liver Int*. 2017 Jan;37 Suppl 1:104-115. doi: 10.1111/liv.13277. Review.
  107. Berzigotti, Annalisa; Albillos, Agustín; Villanueva, Candid; Genescá, Joan; Ardevol, Alba; Agustín, Salvador; Calleja, Jose Luis; Bañares, Rafael; García-Pagán, Juan Carlos; Mesonero, Francisco; Bosch, Jaime; Ciberehd SportDiet Collaborative Group, . (2016). Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study. (In Press). *Hepatology* (Baltimore, Md.) 10.1002/hep.28992

#### **PD Dr. med. Dr. phil. nat. N. Semmo**

108. Golshayan, Déla; Wójtowicz, Agnieszka; Bibert, Stéphanie; Pyndiah, Nitisha; Manuel, Oriol; Binet, Isabelle; Buhler, Leo H; Huynh-Do, Uyen; Mueller, Thomas; Steiger, Jürg; Pascual, Manuel; Meylan, Pascal; Beldi, Guido; Semmo, Nasser; Mohacsi, Paul; Bochud, Pierre-Yves; Swiss Transplant Cohort Study, The (2016). Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. *Kidney international*, 89(4), pp. 927-938. 10.1016/j.kint.2015.11.025



## Dr. Guido Stirnimann

109. De Gottardi, Andrea; Berg, Thomas; Bernardi, M; Berzigotti, Annalisa; Bureau, C; Caca, K; Engelmann, C; Jalan, Rajiv; Klingler, C; Laurent, J; Macdonald, S; Müller, N; Stirnimann, Jessica; Stirnimann, Guido; Zaccherini, G (2016). Management of cirrhotic patients with ascites 1. Uni-Med Science
110. Stirnimann, Guido; Stirnimann, Jessica (2016). Nutrition in cirrhotic patients with ascites. In: Management of cirrhotic patients with ascites (pp. 30-37). Bremen - London - Boston: UNI-MED Verlag AG
111. Calmy, A; van Delden, C; Giostra, E; Junet, C; Rubbia Brandt, L; Yerly, S; Chave, J-P; Samer, C; Elkrief, L; Vionnet, J; Beldi, Guido; Huynh-Do, Uyen; Stirnimann, Guido; Berney, T; Swiss Transplant Cohort Study, STCS (2016). HIV-Positive-to-HIV-Positive Liver Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 16(8), pp. 2473-2478. 10.1111/ajt.13824
112. Mauthner, Oliver; Claes, Veerle; Walston, Jeremy; Engberg, Sandra; Binet, Isabelle; Dickenmann, Michael; Golshayan, Déla; Hadaya, Karine; Huynh-Do, Uyen; Calciolari, Stefano; Beldi, Guido; Stirnimann, Guido; De Geest, Sabina; Swiss Transplant Cohort Study, STCS (2016). ExplorinG frailty and mild cognitive impairmEnt in kidney tRansplantation to predict biomedicAl, psychosocial and health cost outcomeS (GERAS): protocol of a nationwide prospective cohort study. (In Press).
113. Saigi-Morgui, Núria; Quteineh, Lina; Bochud, Pierre-Yves; Crettol, Severine; Kutalik, Zoltán; Wojtowicz, Agnieszka; Bibert, Stéphanie; Beckmann, Sonja; Mueller, Nicolas J; Binet, Isabelle; van Delden, Christian; Steiger, Jürg; Mohacsi, Paul; Stirnimann, Guido; Soccac, Paola M; Pascual, Manuel; Huynh-Do, Uyen; Banz Wüthrich, Vanessa; Beldi, Guido; Eap, Chin B; ... (2016). Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations. PloS one, 11(10), e0164443. 10.1371/journal.pone.0164443
114. Héquet, Delphine; Kralidis, Georg; Carrel, Thierry; Cusini, Alexia; Garzoni, Christian; Hullin, Roger; Meylan, Pascal R; Mohacsi, Paul; Mueller, Nicolas J; Ruschitzka, Frank; Tozzi, Piergiorgio; van Delden, Christian; Weisser, Maja; Wilhelm, Markus J; Pascual, Manuel; Beldi, Guido; Stirnimann, Guido; Manuel, Oriol; Swiss Transplant Cohort Study, STCS (2016). Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections. BMC infectious diseases, 16(321), p. 321. BioMed Central 10.1186/s12879-016-1658-0
115. Trebicka, J; De Gottardi, Andrea; Dell'Era, A; Leebeek, F; Sarin, S; Seijo, S; Valla, D; Primignani, M (2016). Session 6: Consensus Statements – Vascular Diseases of the Liver in Cirrhotic and Noncirrhotic Portal Hypertension. In: Portal Hypertension VI (pp. 421-426). Springer 10.1007/978-3-319-23018-4
116. De Gottardi, Andrea; Berg, Thomas; Bernardi, M; Berzigotti, Annalisa; Bureau, C; Caca, K; Engelmann, C; Jalan, Rajiv; Klingler, C; Laurent, J; Macdonald, S; Müller, N; Stirnimann, Jessica; Stirnimann, Guido; Zaccherini, G (2016). Management of cirrhotic patients with ascites 1. Uni-Med Science

117. Beume, M; Köhler, T; Greub, G; Manuel, O; Aubert, J-D; Baerlocher, L; Farinelli, L; Buckling, A; Stirnimann, Guido; Beldi, Guido; Huynh-Do, Uyen; van Delden, C; Swiss Transplant Cohort Study, . (2017). Rapid adaptation drives invasion of airway donor microbiota by *Pseudomonas* after lung transplantation. *Scientific reports*, 7, p. 40309. 10.1038/srep40309

**Prof. Dr. J. Idle**

118. Wang, Min; Keogh, Adrian; Treves, Susan; Idle, Jeffrey; Beyoglu, Diren (2016). The metabolomic profile of gamma-irradiated human hepatoma and muscle cells reveals metabolic changes consistent with the Warburg effect. *PeerJ*, 4, e1624. 10.7717/peerj.1624

**Dr. D. Beyoglu**

119. Wang, Min; Keogh, Adrian; Treves, Susan; Idle, Jeffrey; Beyoglu, Diren (2016). The metabolomic profile of gamma-irradiated human hepatoma and muscle cells reveals metabolic changes consistent with the Warburg effect. *PeerJ*, 4, e1624. 10.7717/peerj.1624

**Prof. em Dr. M. Solioz**

120. Fischermeier E, Pospisil P, Sayed A, Hof M, Solioz M, Fahmy K. 2017. Membrane lateral pressure regulates dipolar relaxation dynamics at the active site of an ATPase. *Angew Chem Int Ed*, in press.
121. Solioz M. 2016. Copper oxidation state and mycobacterial infection. *Mycobact Dis* 6:210-213.
122. Solioz M. 2016. The copper rush of the nineties. *Metallomics* 8:824-830.
123. Plotnikov EV, Glukhova LB, Sokolyanskaya LO, Karnachuk OV, Solioz M. 2016. Effect of tree species on enzyme secretion by shiitake medicinal mushroom, *Lentinula edodes* (Agaricomycetes). *Int J Med Mushrooms* 18:637-644.
124. Pleskova SN, Gorshkova EN, Novikov VV, Solioz M. 2016. Treatment by serum up-conversion nanoparticles in the fluoride matrix changes the mechanism of cell death and the elasticity of the membrane. *Micron* 90:23-32.
125. Obeid MH, Oertel J, Solioz M, Fahmy K. 2016. Mechanism of attenuation of uranyl toxicity by glutathione in *Lactococcus lactis*. *Appl Environ Microbiol* 82:3563-3571.
126. Mancini S, Kumar R, Abicht HK, Fischermeier E, Solioz M. 2016. Copper resistance and its regulation in the sulfate reducing bacterium *Desulfosporosinus* sp. OT. *Microbiol* 162:684-693.
127. Hans M, Mathews S, Mücklich F, Solioz M. 2016. Physicochemical properties of copper important for its antibacterial activity and development of a unified model. *Biointerphases* 11:018902-1-018902-8



---

## Jahresbericht Hepatologie 2016

Universitätsklinik für Viszerale Chirurgie und Medizin UVC  
Hepatologie  
Inselspital  
3010 Bern  
Tel +41 31 632 87 11  
Fax +41 31 632 49 97

**Prof. Dr. med. Jean-François Dufour,**  
[jean-francois.dufour@dkf.unibe.ch](mailto:jean-francois.dufour@dkf.unibe.ch)  
**Monique Obertin**  
[monique.obertin@dkf.unibe.ch](mailto:monique.obertin@dkf.unibe.ch)  
[www.swissliver.ch](http://www.swissliver.ch)



**SWISSLIVER**